

Docket Number 4-30096/A/CPA

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 334720339US
Express Mail Label Number3/26/2004
Date of Deposit

Address to: MS: CPA
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

This is a request for a **continuation** application under 37 CFR §1.53(d) (continued prosecution application (CPA)) of prior Application No. 09/463,097, filed on January 18, 2000.

Applicant: ZIMMERMANN ET AL.

Title: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS USE

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR §1.51(b), or (2) the national stage of an international application in compliance with 35 USC §371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC §154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR §1.53(d), but must be filed under 37 CFR §1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR §1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC §122 to the extent that any member of the public who is entitled under the provisions of 37 CFR §1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 USC §120 STATEMENT: In a CPA, no references to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC §120 and to every application assigned the application number identified in such request, 37 CFR §1.78(a).

1. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR §1.116 in the prior nonprovisional application.
2. ☒ A Preliminary Amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR §1.53(d)(4). DELETE the following inventor(s) named in the prior nonprovisional application:
4. ☐ A new Declaration and Power of Attorney is enclosed.
5. ☒ An Information Disclosure Statement (IDS) is enclosed:
 - a. ☒ PTO-1449 or similar form
 - b. ☒ Copies of IDS citations
6. ☒ A return receipt postcard is enclosed.
7. ☒ The right to elect an invention or species that is different from that elected in parent Application No. 09/463,097 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.
8. ☐ Other:

04/01/2004 AWONDAF1 00000038 190134 09463097

01 FC:1006 770.00 DA
04/01/2004 09:00:00

Filing fee calculation:

- ☒ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
☒ Before calculating the filing fee, please cancel claims 9 and 11.

Basic Filing Fee								\$	770
Multiple Dependent Claim Fee (\$ 290)								\$	
	For	Number Filed		Number Extra		Rate			
Extra Claims	Total Claims	18	-20		x	\$	18	=	\$
	Independent Claims	5	-3		x	\$	86	=	\$ 172
TOTAL FILING FEE								\$	942

- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$942. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis.

Please address all correspondence to:


- ☒ the present correspondence address for prior Application No. 09/463,097
☐ the address associated with Customer No. 001095, which is currently:


Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (973) 781-8064.

Respectfully submitted,

Date: 3/26/2004


George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
Tel. No. (862) 778-7824



CASE 4-30096/A/CPA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Kindly enter the following preliminary amendment prior to continuing prosecution of this application.